Proceeds Purposes Proceeds from new investors Sailing Capital, certain investment funds for which Clough Capital Partners, L.P. serves as investment manager, and all existing investors, support the immediate initiation of a large Phase 2b, dose-ranging clinical trial to evaluate Metformin DR. An oral agent, Metformin DR is under development to fill the unmet needs of the 40 percent of type 2 diabetes patients who cannot currently use metformin due to contraindications or poor tolerability.